Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients

Table 2 Comparison of the before NAC biomarker status between pCR and non-pCR patients

	pCR				non-pCR				Test	n	p-value
HER2	0	1	2	3	0	1	2	3	Chi-square	189	<0.001*
HER2	3	2	2	19	13	43	64	43	Chi-square	189	<0.001*
ER	-		+		-		+		Chi-square	189	<0.001*
ER	23		3		41		122		Chi-square	189	<0.001*
PR	-		+		-		+		Chi-square	189	<0.001*
PR	25		1		49		114		Chi-square	189	<0.001*
TOPO II	0	1	2	3	0	1	2	3	Chi-square for Ordinal Data	118	0.03*
TOPO II	0	2	5	2	1	58	43	7	Chi-square for Ordinal Data	118	0.03*
EGFR	-	+	++	+++	-	+	++	+++	Chi-square	120	<0.001*
EGFR	1	1	6	1	52	39	16	4	Chi-square	120	<0.001*
Ki67	Mean = 52.81				Mean = 36.40				Mann-Whitney U	189	<0.001*
CK5/6	-		+		-		+		Chi-square	116	0.23
CK5/6	4		3		84		25		Chi-square	116	0.23
AR	Mean = 42.7				Mean = 35.80				Mann-Whitney U	134	0.78
p53	Mean = 43.88				Mean = 26.86				Mann-Whitney U	119	0.07
Tumor size	Mean = 2.75 cm				Mean = 3.94 cm				Mann-Whitney U	189	<0.001*

n is the number of pCR and non-pCR patients having the according information and used for analysis
For categorical biomarkers HER2, ER, PR, TOPO II, EGFR, CK5/6, the number of patients in each category was listed. The HER2 and TOPO II have 4 grading levels: level 0 to level 4. The EGFP have 4 grading levels labeled with -, +, ++ and +++
For biomarkers with continuous values such as Ki67, the mean value was shown in the table
*differences are considered statistically significant at a p-value of less than 0.05

ISSN: 1746-1596